Efficacy and safety of ascending dosages of tribendimidine against hookworm and concomitant soil-transmitted helminth infections in children: a randomized controlled trial

Swiss Tropical and Public Health Institute0 个研究点目标入组 160 人开始时间: 2017年5月19日最近更新: 2019年2月11日

适应症

试验速览

•1. Written informed consent signed by parents and/or legal representative; and oral assent by child
•2. Able and willing to be examined by a study physician at the beginning of the study
•3. Able and willing to provide two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up)
•4. Positive for hookworm eggs in the stool
•5. Absence of major systemic illnesses, e.g. diabetes, severe anemia, clinical malaria as assessed by a medical doctor, upon initial clinical assessment
•6. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease
•7. No recent anthelminthic treatment (within past 4 weeks)
•8. No known allergy to tribendimidine
•9. Age range is 6-12 years old

•1. No written informed consent by parents and/or legal representative
•2. Presence of major systemic illnesses, e.g. diabetes, severe anemia, clinical malaria as assessed by a medical doctor, upon initial clinical assessment
•3. History of acute or severe chronic disease
•4. Recent use of anthelminthic drug (within past 4 weeks)
•5. Attending other clinical trials during the study
•6. Negative diagnostic result for hookworm eggs in the stool

发起方

Swiss Tropical and Public Health Institute